Ageing Lungs: The Hidden Culprit Behind Severe Infections in Older Adults
New research from the University of California, San Francisco (UCSF) is shedding light on why older adults are disproportionately affected by severe outcomes from respiratory illnesses like COVID-19 and the flu. The study, published in the journal Immunity, points to ageing lung cells, specifically fibroblasts, as key instigators of exaggerated immune responses, a phenomenon known as “inflammaging.” This chronic, low-grade inflammation is a hallmark of ageing and can leave the lungs vulnerable to more serious complications.
The findings suggest that these structural lung cells, far from being passive players, actively contribute to the inflammatory cascade that can spiral out of control in older individuals. This discovery could pave the way for innovative treatments aimed at disrupting this destructive cycle before it leads to severe illness.
Unravelling the Inflammatory Mechanism in Ageing Lungs
Researchers conducted a series of experiments using young mice to understand the role of fibroblasts in lung inflammation. They genetically modified these fibroblasts to emit distress signals typically associated with ageing. This allowed them to assess whether these signals, originating from otherwise healthy lung tissue, could trigger detrimental inflammatory responses.
The study revealed a clear pathway:
- Fibroblast Distress Signals: Ageing fibroblasts send out signals that alert the lung to a perceived threat.
- Immune Cell Recruitment: These signals attract immune cells from the bloodstream to the lungs.
- Inflamed Cell Clusters: The influx of immune cells leads to the formation of clusters of inflamed cells within the lung tissue.
- GZMK Cell Involvement: A significant portion of these recruited immune cells were identified as GZMK cells. While these cells were found to be ineffective at combating the infection itself, they contributed to lung damage.
Crucially, the lungs of the young mice, once these inflamed cell clusters formed, exhibited symptoms of advanced infection, mirroring the condition seen in ageing lungs. This suggests that the presence of these inflamed clusters, driven by fibroblast signals, is a primary driver of severe infection symptoms, rather than the ageing of the immune system alone.
The Impact of GZMK Cells and the Promise of Intervention
The researchers were able to demonstrate the critical role of GZMK cells by using a genetic manoeuvre to remove them. When these cells were eliminated, the young mice’s lungs were better equipped to handle the infection, indicating that the ageing lung tissue’s inflammatory signals, amplified by GZMK cells, were the main culprits.
This research also has implications for existing lung conditions. The study highlights that fibroblasts can also play a role in the inflammation seen in diseases like Chronic Obstructive Pulmonary Disease (COPD).
Dr. Tien Peng, a professor of medicine at UCSF and senior author of the study, expressed surprise at the findings. “We were surprised to see lung fibroblasts working hand-in-hand with immune cells to drive inflammaging,” he stated. “It suggests new ways to intervene before patients progress to severe inflammation that can require intubation.”
Human Corroboration: From Mice to Patients
To validate their findings in humans, the UCSF team examined lung tissue samples from older patients hospitalised with severe COVID-related Acute Respiratory Distress Syndrome (ARDS). They observed the same clusters of inflamed cells that were present in the experimental mice.
Furthermore, the study noted a correlation: patients who were sicker tended to have a greater number of these inflamed cell clusters. Conversely, lung tissue from healthy donors did not exhibit these inflammatory aggregations.
A New Therapeutic Frontier
The observed dysfunction between lung and immune cells presents a promising new target for therapeutic development. Dr. Peng commented on the clinical observations during the COVID-19 pandemic: “We saw during COVID that our most vulnerable patients no longer had the infection but still had persistent and devastating lung inflammation. This circuit of dysfunction between lung and immune cells makes for a promising new therapeutic target.”
Looking ahead, the research opens the door to the potential development of therapies that could target these specific GZMK cells directly. Such interventions could help to slow down or mitigate age-related inflammation, offering a new strategy to protect vulnerable populations from the most severe consequences of respiratory infections.





